Adma Biologics, Inc. ADMA
1 trading plan running, 4 Form 144 notices for $6.3M
10-Q, 10-K and Form 144What ADMA's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Dec 5, 2024 to Dec 31, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Adam Grossman President and CEO |
Adopted 10b5-1 plan | Nov 14, 2025 | 10-K Feb 25, 2026 | ||
What the company wroteDuring the quarter ended December 31, 2025, none of our directors or executive officers adopted or terminated any such contract, instruction or written plans except for Adam Grossman, our President and CEO, who entered into a Rule 10b5-1 trading plan with Fidelity Brokerage Services LLC on November 14, 2025 (the “Grossman Plan”). The Grossman Plan provides that Mr. Grossman may sell up to an aggregate of (i) 66,000 shares of our common stock and (ii) 165,000 shares of our common stock to be received upon the exercise of vested options granted to Mr. Grossman. The Grossman Plan is scheduled to terminate on December 31, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Grossman or the broker, or as otherwise provided in the plan. | |||||
| Adam Grossman President and CEO |
Adopted 10b5-1 plan | Dec 5, 2024 | 10-K Mar 18, 2025 | ||
What the company wroteDuring the quarter ended December 31, 2024, none of our directors or executive officers adopted or terminated any such contract, instruction or written plans except for Adam Grossman, our President and CEO, who entered into a Rule 105b-1 trading plan with Fidelity Brokerage Services LLC on December 5, 2024 (the “Grossman Plan”). The Grossman Plan provides that Mr. Grossman may sell up to an aggregate of (i) 60,000 shares of our common stock and (ii) 150,000 shares of our common stock to be received upon the exercise of vested options granted to Mr. Grossman. The Grossman Plan is scheduled to terminate on December 31, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Grossman or the broker, or as otherwise provided in the plan. | |||||
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 10, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 5, 2026 | Grossman Adam S. Director, Officer |
189,000 | $2.0M |
| Mar 10, 2026 | Tade Brad L. Former Officer |
50,026 | $791K |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. Officer |
10,096 | $155K |
| Feb 17, 2026 | Grossman Adam S. Director, Officer |
209,000 | $3.4M |
From the Form 144 XML filed with the SEC, since Feb 17, 2026. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ADMA/export.csv") into a cell.